Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · IEX Real-Time Price · USD
21.75
+17.00 (357.89%)
At close: Mar 28, 2024, 4:00 PM
20.21
-1.54 (-7.08%)
After-hours: Mar 28, 2024, 7:59 PM EDT

Avalo Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019201820172016201520142013
Net Income
-41.66-84.38-63.5-16.07-40.057.77-16.47-10.49-3.52-13.13
Depreciation & Amortization
0.171.661.843.884.550.430.030.020.030.02
Share-Based Compensation
7.558.176.792.532.431.161.690.391.090.75
Other Operating Activities
7.193.6614.33-9.4829.943.220.18-0.09-13.110.87
Operating Cash Flow
-26.75-70.89-40.54-19.13-3.1312.58-14.57-10.16-15.52-11.49
Capital Expenditures
-0.1-0.11-0.06-0.26-0.56-0.02-0.03-0.02-0.02-0.03
Acquisitions
0011.2-0.181.43-18.890000
Other Investing Activities
-----0-----
Investing Cash Flow
-0.1-0.1111.13-0.440.87-18.91-0.03-0.02-0.02-0.03
Share Issuance / Repurchase
0.1173.8644.8813.735.016.39223.6900
Debt Issued / Paid
-14.8132.90-0.260-2.37-3.31-1.819.640
Other Financing Activities
---0.09-0.925.39-0.28-0.11-2.2714.225.42
Financing Cash Flow
-14.7106.7644.7812.5610.43.74-1.4319.623.865.42
Net Cash Flow
-41.5535.7615.38-7.028.14-2.6-16.039.428.32-6.1
Free Cash Flow
-26.85-71.01-40.6-19.4-3.6912.56-14.61-10.18-15.54-11.51
Free Cash Flow Margin
-148.72%-1315.39%-606.09%-287.34%-52.54%45.14%-1266.97%---
Free Cash Flow Per Share
-684.40-1820.68-1560.99-1266.51-305.821964.14-4764.37-13175.15-69697.09-52332.75
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).